Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ralph Corey

Showing results (31-40 of 157) with videos related to

Pageof 16
Sort By:
The Lancet. Infectious Diseases|March 27, 2015
A closer inspection of tedizolid - authors' replyPhilippe Prokocimer, G Ralph Corey, Anita F Das, et al.
The American Journal of Tropical Medicine and Hygiene|July 29, 2009
Persistent eosinophilia and Strongyloides infection in Montagnard refugees after presumptive albendazole therapyNeela D Goswami, J Jina Shah, G Ralph Corey, et al.
Open Forum Infectious Diseases|December 18, 2015
Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve EndocarditisJennifer A Johnson, Eoin R Feeney, David W Kubiak, et al.
Clinical Therapeutics|April 30, 2019
A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Intravenous Drug Use: Phase 3 REVIVE StudiesDavid B Huang, Stephanie Noviello, Barbara Balser, et al.
Nature Reviews. Drug Discovery|December 2, 2009
TelavancinG Ralph Corey, Martin E Stryjewski, Wim Weyenberg, et al.
Antimicrobial Agents and Chemotherapy|August 7, 2015
Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA GuidanceRichard Pushkin, Steven L Barriere, Whedy Wang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2014
Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureusG Ralph Corey, Ethan Rubinstein, Martin E Stryjewski, et al.
Open Forum Infectious Diseases|May 9, 2017
Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical TrialsThomas P Lodise, Mark Redell, Shannon O Armstrong, et al.
BMC Infectious Diseases|April 9, 2014
Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studiesSteven L Barriere, Martin E Stryjewski, G Ralph Corey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2005
A returning traveler with fever and rashDeverick J Anderson, William Fangman, Vance G Fowler, et al.
Pageof 16

Showing results (31-40 of 157) with videos related to

Sort By:
Pageof 16
The Lancet. Infectious Diseases|March 27, 2015
A closer inspection of tedizolid - authors' replyPhilippe Prokocimer, G Ralph Corey, Anita F Das, et al.
The American Journal of Tropical Medicine and Hygiene|July 29, 2009
Persistent eosinophilia and Strongyloides infection in Montagnard refugees after presumptive albendazole therapyNeela D Goswami, J Jina Shah, G Ralph Corey, et al.
Open Forum Infectious Diseases|December 18, 2015
Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve EndocarditisJennifer A Johnson, Eoin R Feeney, David W Kubiak, et al.
Clinical Therapeutics|April 30, 2019
A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Intravenous Drug Use: Phase 3 REVIVE StudiesDavid B Huang, Stephanie Noviello, Barbara Balser, et al.
Nature Reviews. Drug Discovery|December 2, 2009
TelavancinG Ralph Corey, Martin E Stryjewski, Wim Weyenberg, et al.
Antimicrobial Agents and Chemotherapy|August 7, 2015
Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA GuidanceRichard Pushkin, Steven L Barriere, Whedy Wang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2014
Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureusG Ralph Corey, Ethan Rubinstein, Martin E Stryjewski, et al.
Open Forum Infectious Diseases|May 9, 2017
Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical TrialsThomas P Lodise, Mark Redell, Shannon O Armstrong, et al.
BMC Infectious Diseases|April 9, 2014
Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studiesSteven L Barriere, Martin E Stryjewski, G Ralph Corey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2005
A returning traveler with fever and rashDeverick J Anderson, William Fangman, Vance G Fowler, et al.
Pageof 16